Neurodegenerative diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), and Amyotrophic Lateral Sclerosis (ALS), are a complex "family" of pathologies, characterised by the progressive loss of neurons and/or neuronal functions, leading to severe physical and cognitive inabilities in affected patients. These syndromes, despite differences in the causative events, the onset, and the progression of the disease, share as common features the presence of aggregate-prone neuro-toxic proteins, in the form of aggresomes and/or inclusion bodies, perturbing cellular homeostasis and neuronal function (Popovic et al., 2014) , and the presence of dysfunctional mitochondria. The removal of protein aggregates and of damaged organelles, through the ubiquitin-proteasome system (UPS) and/or the autophagy/lysosome machinery, is a crucial step for the maintenance of neuronal homeostasis. Indeed, their impairment has been reported as associated with the development of these diseases. In this review, we focus on the role played by mitophagy, a specialised form of autophagy, in the onset and progression of major neurodegenerative diseases, as well as on possible therapeutic approaches involving mitophagy modulation.
Introduction
Neurons are a very specialised cell population showing a peculiar architecture and high energy demands in order to function properly (Belanger et al., 2011) . In particular, they show high demands for mitochondria and, as post-mitotic non-proliferating cells, their organelles are prone to accumulate oxidative damage and should cope with high levels of Ca 2þ . The ability of these cells to maintain protein and organelle homeostasis is a critical factor to ensure not only their functionality but also their viability (Bakthavachalam and Shanmugam, 2017) . To achieve this aim, neurons rely on the activity of both the ubiquitin-proteasome system (UPS) and the autophagy/lysosome pathway. Failures in one of these systems lead to the accumulation of misfolded and/or aggregated proteins, which together with dysfunctional mitochondria are the hallmarks of most neurodegenerative diseases (Popovic et al., 2014) . In more details, i) Parkinson's disease (PD, the second most common progressive disorder of the central nervous system), is characterised by a loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), and by the formation of intra-neuronal protein aggregates of a-synuclein, called Lewy body, which are cleared by autophagy (Webb et al., 2003) ; ii) Alzheimer's disease (AD) is characterised by brain atrophy, associated with both neuronal and synaptic loss, accumulation of amyloid b plaques, and intracellular neuro-fibrillary tangles of phosphorylated Tau protein (Harrington, 2012) . Mitochondrial dysfunction, the major causative event in AD (Friedland-Leuner et al., 2014) , has been related to the accumulation of both amyloid precursor protein (APP) and amyloid b (Ab) peptides on these organelles; iii) Huntington's disease (HD)
is characterised by motor dysfunction, cognitive decline and psychiatric disturbances (Ross and Tabrizi, 2011) . CAG trinucleotide repeats expansion results in the presence of large polyglutamine (polyQ) stretches at the N-terminal of the huntingtin (Htt) protein.
HD pathogenesis relies on different mechanisms, among which differential mHtt proteostasis, leading to the appearance of cellular inclusions, and mitochondrial dysfunction (Guedes-Dias et al., 2016) ; iv) Amyotrophic Lateral Sclerosis (ALS) is a progressive paralytic disease, caused by selective loss of upper and lower motor neurons in the brain and spinal cord. The most common form is sporadic ALS, and only 5e10% of all ALS cases are inheritable. Several genes have been reported as associated with familial and sporadic ALS, including superoxide dismutase 1 (SOD1), RNAbinding protein FUS, and TAR DNA-binding protein 43 (TDP43) (Andersen and Al-Chalabi, 2011 ). In addition, other factors, including oxidative stress and mitochondrial dysfunction are known to cause sporadic ALS (Kiernan et al., 2011) . The understanding of the role played by cellular mechanisms involved in the dismissal of misfolded, damaged and/or long-lived protein, as well as of dysfunctional/damaged mitochondria, received increasing attention in recent years. In particular, growing evidence support a central role for a specialised form of autophagy, called mitophagy, which is responsible for the selective dismissal of dysfunctional/damaged mitochondria, in the onset and progression of these syndromes (Wong and Holzbaur, 2015) .
Alterations of the ubiquitin-proteasome system in neurodegenerative diseases
The UPS is a very complex and evolutionary conserved mechanism allowing for the conjugation of ubiquitin, through the action of different E3-ligases, to target proteins, in order to promote their clearance through the proteasome (Pickart, 2001) . The presence of ubiquitin within proteins aggregates has been reported for AD, PD and polyQ disorders, strongly suggesting that an imbalance between ubiquitinating and de-ubiquitinating systems could play a crucial role in the onset and progression of neurodegenerative diseases (Todi and Paulson, 2011; Popovic et al., 2014) . In fact, a decline in the UPS functionality has been observed in brain tissues of the Tg2576 AD mouse model (overexpressing a mutant form of the Amyloid Precursor Protein, APP), and also exogenous Ab administration results in the attenuation of proteasome activity in vitro (Oh et al., 2005) (Fig. 1 ). In addition, in the APPswe/ PSEN1DE9 AD mouse model, some E3-ligases, among which Parkin, have been reported as down-regulated; in line with that, when Parkin is over-expressed in the same context, it has been observed i) a restoration of the synaptic plasticity, ii) a rescue of the behavioural abnormalities, iii) a reduction of APP protein expression, and iv) a decrease in b-amyloid load and inflammation (Hong et al., 2014) . A quite similar scenario has been reported in brains of PD patients, in which the presence of ubiquitin-positive Lewy bodies (Kuzuhara et al., 1988) has been associated with impaired UPS activity in the substantia nigra (McNaught and Jenner, 2001) . Moreover, mutations in genes encoding Parkin (Kitada et al., 1998) , DJ-1 (Bonifati et al., 2003) , and Pink1 , which could form an E3 ligase complex able to promote unfolded protein degradation (Xiong et al., 2009) , have been identified in familial PD (Fig. 1) . In addition, the reported increased expression of TRAF6 (Chung et al., 2013) could be responsible for the formation of polyubiquitinated DJ-1 aggregates, whilst TRAF6 down-regulation affects Pink1 localisation and stabilisation on dysfunctional mitochondria (Murata et al., 2013) . As for PolyQ diseases, ubiquitin linked to mutated huntingtin has been detected in neuronal inclusions in the cortex and striatum of HD patients (DiFiglia et al., 1997) ; also, it has been reported that the eukaryotic UPS could not clear protein stretches containing more than 25Q residues (Venkatraman et al., 2004) . Further, spinocerebellar ataxia type 3 (SCA3), is a polyQ disease caused by a CAG expansion in the gene encoding for Ataxin-3 (Kawaguchi et al., 1994) , a deubiquitinating enzyme, containing a ubiquitin interacting motif flanking the polyQ domain. It has been reported that over-expression of normal human Ataxin-3 can protect Drosophila from polyQ-huntingtininduced neurodegeneration (Warrick et al., 2005) , while mutant Ataxin-3 can promote parkin clearance, throughout autophagy (Durcan et al., 2011) . In ALS, misfolded and aggregated proteins, such as SOD1, TDP-43 and FUS/TLS, were found to be early removed by the UPS system (Andersen and Al-Chalabi, 2011; Guo et al., 2010; Rossi et al., 2016) .
All these evidence point to UPS as an important (although not unique) player in the maintenance of neuronal proteostasis (Fig. 1) . In fact, the UPS system works in accordance with the autophagy machinery in order to remove bulk protein aggregates and/or damaged organelles, which are too large to enter the proteasome. This aspect is particularly relevant as the accumulation of mutated and/or misfolded proteins on mitochondria , could lead not only to organelle's dysfunction, but also to macroand specialised-autophagy impairment as well as to perturbation of mitochondria dynamics.
Macro-and selective-autophagy in neurodegenerative diseases
Macroautophagy, herein termed autophagy, is a conserved intra-cellular process responsible for the degradation of long-lived or damaged proteins and organelles, and bulk protein aggregates (for a review see (Garcia-Arencibia et al., 2010) , through the formation of double-membrane vesicles, the autophagosomes, which enclose cytoplasmic components and deliver them to lysosomes (Fig. 1) . The so formed autophagolysosome is the subcellular structure responsible for the degradation of cytosolic macromolecules and organelles, thus providing a way of recycling to fuel cell metabolism (Mizushima and Komatsu, 2011) . Autophagy, initially characterised as a nutrient deprivation-induced bulk and nonselective degradation pathway, also contributes to intracellular homeostasis in non-starved cells. In particular, is the process responsible for the degradation of different materials, such as aggregate-prone proteins, including those causing many neurodegenerative conditions (aggrephagy), damaged mitochondria (mitophagy), excess peroxisomes (pexophagy), and invading pathogens (xenophagy) (Stolz et al., 2014) . Such a tightly regulated mechanism depends upon the activation of sensor kinases, such as the 5 0 AMP-activated protein kinase (AMPK) or the Serine/ threonine-protein kinase ULK1, and the Beclin 1 and PI3K complexes (Nazio et al., 2016; Papinski and Kraft, 2016) . Coordinated induction/repression of autophagy is thus a crucial step in the maintenance of cellular homeostasis in post-mitotic cells, such as neurons.
Neurodegenerative diseases are characterised by a complex heterogeneity of phenotypes and causative events. However, for all major neurodegenerative diseases, there are familial forms which could be extremely informative about the possible pathogenesis mechanisms. Several genes identified as disease-associated show the potential involvement of autophagy in the onset and progression of these syndromes. The complexity of the autophagy pathway, as well as of its fine regulation, makes quite difficult, and in some cases controversial, to really determine which of the different steps is affected in these syndromes (Fig. 1) .
Indeed, autophagy initiation could be affected by reduced levels of Beclin 1 mRNA and protein, as observed in AD (Pickford et al., 2008) ; mutations in the a-synuclein (SNCA) (Tanik et al., 2013; Winslow et al., 2010) and LRKK2 (Schapansky et al., 2014) , as detected in PD; formation of mutated huntingtin (mHtt)/Beclin 1 (Shibata et al., 2006) , mHtt/Rhes (Mealer et al., 2014) , and mHtt/ mTOR (Menzies et al., 2017) aggregates, as reported in HD; mutations in the C9ORF72 gene (DeJesus-Hernandez et al., 2011), as described for ALS.
The elongation, cargo recognition and completion steps could be affected by alterations in the levels of the clathrin adaptor protein PICALM, as reported in AD (Moreau et al., 2014) ; hyperphosphorylated Tau-dependent microtubules destabilisation, as in AD and PD (Hamm et al., 2015) ; defective cargo recognition/interaction, as reported for mHtt in HD, or TDP-43, SOD1 and FUS, in ALS (Menzies et al., 2017) .
The final fusion and degradation steps could be affected by both blockade of the autophagosome/lysosome fusion process, i.e. PS-1 mutations in AD and VPS35 in PD, as well as by impairment of lysosomal functions, as reported for ATP13A2 (PARK9) loss of function mutants (Dehay et al., 2012) .
All these evidence point to a key role for autophagy in the balance between health and disease in these syndromes. Moreover, besides the accumulation of intra-and extra-cellular protein aggregates, and the alterations of the homeostatic machinery, one of the hallmarks of neurodegenerative disorders is mitochondria dysfunction. Neurons are highly energy demanding cells. For this reason, mitochondria are key organelles for these cells and need to be maintained in perfect efficiency, in order to provide the requested energy.
Mitochondria dynamics in neurodegenerative diseases
Mitochondria are organised in a very dynamic network that undergo continuous fusion and fission, in order to exert their functions in the most appropriate way at every time. In mammals, fusion is regulated by the dynamin-related GTPases Mitofusin 1 and 2 (Mfn1 and Mfn2), responsible for the fusion of the outer mitochondrial membranes, and optic atrophy 1 (OPA1), responsible for the fusion of the inner mitochondrial membranes. Fission is under the control of the dynamin-related protein 1 (Drp1), a cytosolic GTPase recruited to mitochondria by four mitochondrial receptor proteins: fission 1 (Fis1), mitochondria fission factor (Mff), mitochondria dynamics protein of 49 kDa (MID49) and MID51 (Mishra, 2016) . The balance between fusion and fission is crucial for the integrity of the mitochondrial network, and depends i) upon posttranslational modification of these factors, such as Drp1 phosphorylation (Cribbs and Strack, 2007) , ubiquitination (Peng et al., 2016 ), or SUMOylation (Harder et al., 2004 , and ii) on the interactions between mitochondria and the Endoplasmic Reticulum (ER), being Drp1 and Mfn2 also localised at the ER-mitochondria contact sites (Friedman et al., 2011) . In addition, network rearrangements and mitochondria distribution inside the cells rely on their transport along the microtubule cytoskeleton, through the action of both kinesin and dynein motor proteins (Saxton and Hollenbeck, 2012) . The Mitochondrial Rho GTPase (Miro), located on the outer membrane, directly interacts with the adapter protein Milton, in order to link mitochondria to the motor proteins. In addition, Mfn1 and Mfn2 are able to interact with the Miro/Milton complex, and Mfn2 has been reported as relevant for axonal mitochondrial delivery in neurons (Misko et al., 2010) .
Fission and fusion seem to act as a highly selective quality control mechanism, able to "segregate" damaged or dysfunctional mitochondria from the network, thus allowing their clearance through mitophagy [(Twig et al., 2008 ) and see below]. Interestingly, over-expression of mitophagy regulators PINK1 and Parkin leads to Miro ubiquitination and degradation, with the appearance of perinuclear clustered mitochondria, then removed by mitophagy (Liu et al., 2012b) . Miro1 turnover is impaired in fibroblasts of PD patients with mutated Parkin, this suggesting the importance of mitochondrial network rearrangements in order to isolate dysfunctional organelles and for their transport back to the soma for removal (Birsa et al., 2014) . Further, fragmented mitochondria were also observed when pathogenic a-synuclein (A53T or A30P) is over-expressed, probably as a consequence of OPA1 cleavage (Guardia-Laguarta et al., 2014) . Moreover, autosomal dominant PD patients, bearing the G2019S mutations in the LRRK2 (PARK8) gene, showed decreased mitochondria membrane potential and elongated mitochondria. Mitochondria dynamics are relevant also in AD, as knockdown of Miro or Milton results in increased levels of tau phosphorylation at Ser262, a key step on AD onset. Furthermore, cells bearing the E280A presenilin-1 (PS-1) mutation, showed a reduction of Miro1 protein levels and an impairment of mitochondrial/ER tethering and transport (Sepulveda-Falla et al., 2014) . As for HD and ALS, the picture is still foggy, but there are evidence about the involvement of mitochondria dynamics in the onset and progression of the disease (Carri et al., 2017; Guedes-Dias et al., 2016) . In fact, late-stage patients and HD mice models exhibit increased mRNA and protein levels of Drp1 and Fis1, associated with decreased levels of mitofusins, suggesting that mitochondria dynamics are unbalanced towards fission (Costa and Scorrano, 2012; Oliveira and Lightowlers, 2010; . How mHtt impairs mitochondrial fission-fusion equilibrium is yet to be understood, but it has been proposed that mHtt may promote fission via direct interaction with or indirect induced modification of Drp1 (Chang and Blackstone, 2010; Song et al., 2011) . Mitochondria network fragmentation, associated with increased expression of Drp1 and Fis1 and decreased expression of OPA1 and mitofusins, were reported for SOD1 and ALS-linked mutant TDP43 transgenic mice . Further, Miro1 protein levels have been shown to be significantly reduced in spinal cord tissues of both ALS patients and G93A-SOD1 or M337V-TDP43 mice models (Zhang et al., 2015b) .
Altogether, these observations lead to the idea that mitochondria network dynamics work in tight collaboration with the mitophagy pathway, to ensure the quality of these organelles.
Mitophagy
Mitophagy is a selective form of autophagy, devoted to the elimination of dysfunctional mitochondria, and is a crucial quality control mechanism to ensure mitochondrial network's integrity and functionality. In physiological settings, mitophagy is also responsible for mitochondrial dismissal during erythrocyte maturation, and it contributes to maternal inheritance of mitochondrial DNA, by eliminating the sperm-derived mitochondria (Ashrafi and Schwarz, 2013) . As for macroautophagy, a number of specific protein regulators control the mitophagy process, in order to ensure the selective sequestration of those mitochondria who need to be eliminated, in the forming autophagosome. In mammals, there are both Parkin-dependent and Parkin-independent pathways of mitophagy. In Parkin-dependent mitophagy, damaged/ dysfunctional mitochondrial are removed by the concerted action Fig. 1 . Impairment of the Ubiquitin Proteasome pathways (UPS) and Autophagy in neurodegenerative diseases. In healthy neurons, UPS and autophagy contribute to the removal of outlived protein and organelles, such as mitochondria. In neurodegenerative diseases, accumulation of misfolded/mutated protein aggregates and mutations in ubiquitinating enzymes result in a reduced UPS activity. On the other hand, defective autophagy results from impairments in the initiation step (AD, PD, HD), and in cargo recognition (AD, ALS), mainly due to the presence of mutated protein aggregates; in the trafficking of the autophagic vesicles (AD, PD, ALS), and in the fusion with lysosomes (AD), mainly due to alteration of the microtubule network, impairment of dynamins/kinesins activities, and lysosomal efficiency.
of the PTEN-induced putative protein kinase 1 (PINK1) and of the E3 ubiquitin ligase Parkin. PINK1 and Parkin accumulate on damaged mitochondria, flagging these organelles with Parkindependent ubiquitination of outer membrane proteins, thus allowing their autophagic degradation (Eiyama and Okamoto, 2015; Geisler et al., 2010) (Fig. 2) . In the PINK/Parkin independent pathway, different protein regulators, such as BNIP3L (Sandoval et al., 2008) , FUNDC1 (Liu et al., 2012a) , cardiolipin (Chu et al., 2013) and AMBRA1 , contributes to the flagging and recognition of mitochondria. Efficient mitophagy relies on the engulfment of the damaged organelles into the onforming autophagosome, without affecting the entire mitochondrial network. For this reason, mitochondrial network fragmentation is observed prior to mitophagy, which thus results to be strictly connected with mitochondria dynamics and the machineries controlling the balance between fusion and fission of the organelles. in fact, not only the main pro-fission protein Drp1 is modulated trough post-translational modifications such as SUMOylation, but also proteins favouring the fusion and transport of the organelles -such as Mfn2 or Miro, are selectively degraded in order to finally promote mitochondrial fission . Notably, defects in both autophagy and mitophagy have been reported as important at the onset and progression of neurodegenerative diseases (Fig. 2) .
Mitophagy in Parkinson's disease
Autosomal recessive PD is associated with the presence of mutations in the PARK2 gene, coding for the Parkin protein (Kitada et al., 1998; Lucking et al., 2000; Mata et al., 2004; Periquet et al., 2003) , and in the PARK6 gene encoding the PINK1 protein (Valente et al., 2001 (Valente et al., , 2002 . PINK1 and Parkin are key factors acting on the same biological pathway, leading to the tagging and engulfment of dysfunctional mitochondria, by the autophagy machinery (Pickrell and Youle, 2015) . PINK1 is a mitochondrial resident protein, which is rapidly degraded after its import into healthy organelles, by the action of mitochondrial matrix protease (MMP) and the Presenilin-associated rhomboid-like protein (PARL) (Greene et al., 2012) . Whereas, in dysfunctional mitochondria, i.e. depolarised organelles, PINK1 is not degraded and it accumulates on the outer mitochondrial membrane (OMM) (Narendra et al., 2010) . OMMlocalised PINK1 could directly phosphorylate cytosolic Parkin, as well as mitochondrial ubiquitin chains, thus providing signals for Parkin recruitment to the damaged organelle (Durcan and Fon, 2015; Narendra et al., 2008) . Parkin is a cytosolic E3-ubiquitin ligase, whose activity is strongly stimulated once recruited to mitochondria and is responsible for flagging such dysfunctional mitochondria with phosphorylated-ubiquitin. Indeed, Parkin mediates the ubiquitination of the mitochondrial outer membrane proteins, among which Mfn1 and Mfn2, Miro, the translocase of outer mitochondrial membrane 20 (TOMM20), and the voltagedependent anion channel (VDAC1). Ubiquitinated Mfn1 and Mfn2 are delivered to the proteasome for degradation, thus stimulating mitochondrial fission and network fragmentation (Gegg et al., 2010) , while other ubiquitinated proteins are recognised by autophagy receptors, such as p62 and Optineurin (Wong and Holzbaur, 2014a) , allowing their selective engulfment in the onforming autophagosome (Itakura et al., 2012) . The mitophagy process acting through PINK1/Parkin seems to be important not only to protect neurons from the damage caused by dysfunctional mitochondria in the soma, but it has been proposed that this system could be very efficient in the removal of damaged organelles in distal axons of these cells (Ashrafi et al., 2014) . Perturbation of the system in PD patients, could depend upon both mutations in the genes encoding key proteins in the system , but also on altered Parkin solubility, as a consequence of age (Pawlyk et al., 2003) or oxidative and/or nitrosative stress Winklhofer et al., 2003) . In addition, a number of different proteins have been identified as important for interacting with and/or being able to modify the PINK1/Parkin pathway (Pickrell and Youle, 2015) . Notably, among them there are proteins, which are able to antagonise Parkin activity, such as the anti-apoptotic members of the Bcl-2 family Bcl-X L and Mcl-1, or the deubiquitinases USP30 (Bingol et al., 2014) and USP15 (Cornelissen et al., 2014) . On the other side, Parkin activity is induced by the deubiquitinase USP8 (Durcan et al., 2014) , and mitophagy is induced by its interaction with AMBRA1 (Van Humbeeck et al., 2011) , whose localisation on the OMM induces mitophagy even in the absence of Parkin . The relevance of Parkin-independent mitophagy activation has yet to be addressed in PD, as other E3-ligases have been identified as able to flag mitochondria towards removal; indeed, it has been very recently proposed that PINK1-generated phosphoubiquitin on the mitochondria is the main signal for mitophagy and that Parkin acts as an amplifier in the system (Lazarou et al., 2015) . However, Parkin-mediated mitophagy is supposed to be a rare event in vivo, and Parkin-mediated mitophagy could rather act as a protective mechanism against those mitochondria in the network that show severe or quite complete loss of membrane potential (Sterky et al., 2011) . In addition, Parkin could exert its E3 ligase activity on different substrates, targeting them for proteasome degradation. Some of them are implicated in the autophagy/ mitophagy process, such as p62 , and the impairment of the parkin/p62 axis could increase a neuron's vulnerability in PD; or in the regulation of the mitochondrial clearance/biogenesis balance, such as the PGC-1a transcriptional repressor PARIS (Shin et al., 2011) , whose overexpression in conditional Parkin-deficient mice, leads to dopaminergic neuron loss. It remains to be fully understood which is the real contribution of Parkin, and may be other mitophagy regulator proteins, in the onset and progression of neurodegenerative diseases, also in the light of its involvement in other pathologies, such as AD and ALS (Zhang et al., 2015a) .
Mitophagy in Alzheimer's disease
Mitochondrial dysfunction in AD is due to the accumulation of both APP and Ab peptides on these organelles. In particular, Ab toxicity could depend upon: i) its interaction with mitochondrial matrix proteins (Du et al., 2008; Lustbader et al., 2004) ; ii) the perturbation of the fission and fusion processes Manczak and Reddy, 2012a) ; iii) the alteration of mitochondrial motility ; iv) the disruption of the functionality of the electron transfer chain and of the ATP/ADP exchange (Manczak and Reddy, 2012b) . Among these events, the molecular mechanism underlying the perturbation of the fission/fusion equilibrium is still controversial, as there are reports underlying both reduction and increased expression of the mitochondrial pro-fission proteins Drp1 and Fis1 (Cho et al., 2009; Wang et al., 2008) . Nevertheless, it is quite clear that the abnormal mitochondrial network fragmentation observed in AD is due to the interaction of Drp1 with Ab and phosphorylated tau, which is increased during AD progression (Kandimalla and Reddy, 2016) . Accumulation of autophagic vacuoles (AVs) in AD brains suggested defective autophagy as one of the pathogenic features of AD (Nixon, 2013; Nixon et al., 2005) . Very recently, it has been reported that although the autophagic machinery is competent in AD neurons, the flux is impaired in the final stages of the process, namely the fusion of autophagosomes with lysosomes (Bordi et al., 2016) . In line with this observation, mutant neurons from both hAPP transgenic mice, harbouring the human AD Swedish and Indiana mutations (J20), and AD patient brains showed strong induction of Parkin-mediated mitophagy, due to increased recruitment of Parkin to damaged mitochondria. During disease progression, enhanced mitophagy couple with the depletion of cytosolic Parkin, this leading to accumulation of dysfunctional mitochondria (Ye et al., 2015) . In addition, it has been reported that Parkin over-expression in an AD mouse model results in an enhancement of the autophagic clearance of defective mitochondria, and in the prevention of mitochondrial dysfunction (Khandelwal et al., 2011; Martin-Maestro et al., 2016) . Taken together these observations suggest that whereas enhanced mitophagy increases the autophagic flux, defective lysosomal removal of the AVs is responsible for the aberrant accumulation of defective mitochondria in AD. Further, it has been very recently reported that N-terminal truncated Tau is able to induce aberrant Parkin recruitment, thus leading to excessive mitophagy, contributing to synaptic failure (Corsetti et al., 2015) .
Mitophagy in Huntington's diseases
Defective removal of dysfunctional mitochondria observed in HD suggested an impairment in the mitophagy process. It has been proposed that mHtt could impair the delivery of flagged dysfunctional mitochondria to onforming autophagosomes, because of its reduced interaction with the autophagy receptor SQSTM1/p62 (Martinez-Vicente et al., 2010) , and by affecting autophagosome transport towards the lysosome (Wong and Holzbaur, 2014b) . Recently, it has been observed that Htt is massively involved in selective autophagy, by serving as a scaffold for both SQSTM1/p62 and the autophagy initiation kinase ULK1 (Rui et al., 2015) , reopening the question about the role of mHtt in these processes. A partial answer has been suggested by the observation that a reduced delivery of dysfunctional mitochondria to the autophagosome could be partially rescued when PINK1 is over-expressed, in fly and mice HD models (Khalil et al., 2015) . Even if it does not seem that mHtt affects basal autophagy levels (Baldo et al., 2013) , a lower autophagic flux (Guedes-Dias et al., 2015) and differential expression of autophagy regulators/effectors, such as GABARAPL1 (Le Fig. 2 . Impairment of mitophagy in neurodegenerative diseases. The removal of damaged mitochondria through mitophagy is achieved by both PINK1/Parkin-dependent and -independent mechanisms. In healthy mitochondria, sustained mitochondrial membrane potential (DJ) allows for the translocation of PINK1 protein inside the organelle, where it is rapidly degraded by mitochondrial processing protease (MPP) and the Presenilins-associated rhomboid-like protein (PARL). In damaged or dysfunctional mitochondria, loss of MMP and/or accumulation of misfolded/mutated proteins, does not allow for the transfer of PINK1 through TOM/TIM complexes, thus accumulating the protein on the outer mitochondrial membrane (OMM). On the mitochondrial surface, PINK1 auto-phosphorylation signals for the recruitment of the cytosolic E3-ligase Parkin, which is then able to ubiquitinate mitochondrial proteins on the OMM (Bingol and Sheng, 2016) , thus flagging damaged/dysfunctional organelles for recognition by onforming autophagosomes. In Parkin-independent mitophagy, other proteins (BNIP3l, FUNDC1, AMBRA1) are able to translocate on the OMM, where they could serve as direct or indirect signals for the engulfment within the onforming autophagosome. In neurodegenerative diseases, mutations in the key proteins PINK1 and Parkin could result in either an impairment or an activation of the mitophagic process. Moreover, the action of anti-apoptotic factors, such as Mcl-1 and Bcl-X L , and of de-ubiquitinases, such as USP30 and USP15, have been reported to impact the action of Parkin; by contrast, AMBRA1 has been reported as a positive modulator of Parkin activity. In both Parkin-dependent and -independent mitophagy, the presence of mutated/misfolded protein aggregates affects the removal of damaged/ dysfunctional mitochondria through mitophagy, possibly by limiting their recognition by the onforming autophagosome. Grand et al., 2013) and AMBRA1 (Sepe et al., 2014) , have been reported in diverse neuronal populations. In addition, the analysis of Pink1 À/À mice indicates that mitophagy levels are very different in various areas of the brain (Diedrich et al., 2011) , thus suggesting that different neuronal population could rely on or modulate different forms of Parkin-dependent/Parkin-independent mitophagy, probably in response to different stimuli.
Mitophagy in Amyotrophic Lateral Sclerosis
Alteration of the autophagic/lysosomal system has been reported in the ALS mouse model, with contrasting evidences showing both autophagy impairment and induction (Morimoto et al., 2007; . Sporadic-ALS patients, indeed, exhibit autophagic vesicles in the cytoplasm of normal motor neurons, which became more evident in degenerated motor neurons (Sasaki, 2011) . Moreover, even though various studies suggest that autophagic clearance of mutated SOD1 could be beneficial (Crippa et al., 2010a (Crippa et al., , 2010b Han et al., 2015; Hetz et al., 2009; Li et al., 2008) , increased lifespan has been observed in mutant SOD1 transgenic mice haploinsufficient for BECN1 (Nassif et al., 2014) . The implication of autophagy in ALS is also supported by the study of the function of other ALS-related genes, such as ALS2/ alsin, recently shown to contribute to the endosomeautophagosome trafficking (Hadano et al., 2010) , and TDP43, an RNA-binding protein involved in RNA processing, whose turnover is enhanced by autophagy activation. Also, autophagy-activating compounds improve TDP43 clearance and enhance neuronal survival in ALS models (Barmada et al., 2014) . These observations suggested that autophagic degradation of mutant SOD1 and TDP43 could be beneficial to ALS, but it is not clear yet whether pharmacological modulation of the process could effectively be a pathology reliever in ALS. In fact, while autophagy enhancement through rapamycin showed both beneficial and detrimental effects in ALS models (Staats et al., 2013; Zhang et al., 2011) , trehalose administration, results in SOD1 decrease and p62 aggregation, ubiquitinated protein accumulation, and in the inhibition of apoptosis in SOD1G93A mice (Zhang et al., 2014) . Lithium, similar to rapamycin, has been shown to exert opposite effects, by delaying disease progression in patients, and showing protective effects in the SOD1G93A ALS mouse model (Fornai et al., 2008) . On the other hand, another report showed that lithium was not able to ameliorate disease progression in SOD1G93A mice (Pizzasegola et al., 2009) .
Mitochondrial dysfunction in ALS is widely studied, as alterations in mitochondrial morphology, fusion/fission dynamics and biogenesis are considered relevant for ALS onset and progression (Carri et al., 2017; Cozzolino et al., 2013) . Mutant SOD1 has been shown to impair mitochondrial retrograde axonal transport , coupled with mitochondrial network fragmentation (Vande Velde et al., 2011) , this suggesting mitophagy induction. Notably, defective retrograde transport of autophagosomes, as well as consumption of rate-limiting components, could result in a delay in the mitophagic flux in mutant SOD1 neurons. It has been proposed that, in neurons, efficient mitochondrial quality control depends upon both Parkin-dependent and -independent pathways. Cellular and animal models of TDP-43 and FUS depletion, as well as samples from ALS spinal cord, showed a decrease in the RNA level of Parkin, suggesting a possible increased vulnerability to mitochondrial dysfunction Polymenidou et al., 2011) . The observation that over-expression of mutated TDP-43 results in the depletion of Parkin (Stribl et al., 2014) , suggested that the accumulation of mutant and misfolded TDP-43 and/or SOD1 proteins on mitochondria might interfere with the normal PINK1/Parkin dependent mitophagy. Interestingly, Parkin over-expression was able to induce TDP-43 ubiquitination and re-localisation, reverting the phenotype (Hebron et al., 2013 (Hebron et al., , 2014 . Mitophagy induction in ALS is supported by the evidence of an increase of LC3II in neurons of SOD1 transgenic mice (Li et al., 2008; Morimoto et al., 2007) , as well as by the accumulation of mitochondria containing autophagosomes and autophagolysosomes in human spinal cord ALS samples (Sasaki, 2011) . Notably, G93A-mutant SOD1 transgenic mice show progressive accumulation of p62 in the spinal cord (Gal et al., 2007) , and it has been reported that mutant SOD1 can bind p62 and LC3 directly, so as to favour the sequestration of mutant SOD1 into cytoplasmic inclusions and their delivery to autophagosomes (Gal et al., 2009) . Defective recognition of ubiquitin-flagged dysfunctional mitochondria by autophagosome receptors has been proposed as a mechanism impairing efficient mitophagy in ALS (Majcher et al., 2015) . Recently, it has been reported that the ALS-associated E478G mutation in the ubiquitin-binding domain of Optineurin, one of the autophagy receptor for autophagosome formation around mitochondria, effectively leads to defective mitophagy and accumulation of damaged mitochondria (Wong and Holzbaur, 2014a) .
Therapeutic modulation of mitophagy
The sociological and financial impact of neurodegenerative diseases is growing year by year (Olesen et al., 2012) , and the research of new therapeutic approaches is a compelling need of our and future times. Gene therapy able to replace defective genes with fully functional ones would be the best solution, but still too far to come. Nowadays, the best candidates for therapy remain small molecule drugs, some of them already in clinical trials, able to induce cellular processes involved in the clearance of protein aggregates and dysfunctional mitochondria (Chaturvedi and Beal, 2013; Nah et al., 2015) . In general, it appears that autophagy induction could be beneficial for neurodegenerative diseases. Nevertheless, great care should be taken, as the picture is not so simple and the same for every pathology. As an example, autophagy-inducing agents can prevent the accumulation of plaques and tangles, in the early stage of AD. However, in the late stage of the pathology, when autophagosome/lysosome fusion or lysosomal function is impaired, autophagy induction could severely aggravate the phenotype (Ching and Weihl, 2013) . Since mitochondrial dysfunction has been associated with all the major neurodegenerative diseases, the search for molecules able to induce the selective removal of damaged organelles has attracted great interest in recent years. Unfortunately, the compounds routinely used to trigger mitophagy in vitro, such as FCCP or antimycin/oligomycin combinations, results to be very toxic and not so specific (Maro et al., 1982; Padman et al., 2013) , and trigger nonphysiological levels of mitophagy (Vives-Bauza et al., 2010) . The ideal molecule should be able to restore or boost endogenous mitochondrial quality control mechanisms. Recently, p62-mediated mitophagy inducer (PMI) has been described as able to induce NRF2-dependent expression of antioxidant response genes, among which p62. Increased expression and localisation of p62 on mitochondria results in the activation of mitophagy, independently from the PINK1/Parkin pathway, and without inducing mitochondrial membrane potential loss. This molecule seems to be an ideal candidate for delivering dysfunctional mitochondria to the process of quality control, without compromising the bio-energetic competence of the whole network (East et al., 2014) .
Further, Ambra1 targeting to mitochondria has been shown to be sufficient to induce mitoaggresomes formation and massive mitophagy in a number of Parkin-dependent and -independent systems (Strappazzon et al., 2015) . Molecules enabling Ambra1 translocation to mitochondria may thus represent innovative tools to induce mitophagy in vivo.
Conclusions
Mitochondrial dysfunction and dismissal of mutated/misfolded proteins are prominent features of the major neurodegenerative disease. In the last years, it has become quite clear that there is a complex interconnection between the two principal systems granting cellular homeostasis, namely UPS and autophagy. The mitochondrial quality control involves multiple levels of surveillance and seems to be one of the most attractive target for therapeutic intervention in these diseases. Nevertheless, this goal is far to be achieved as mitochondrial fusion and fission equilibrium, mitochondrial transport and distribution between the axon and the soma, as well as the removal of aged and damaged organelles, are under the control of diverse and complex cellular mechanisms. Among them, mitophagy is the key pathway for mitochondrial quality control, linking in a complex network mitochondrial fusion, fission, transport, and dismissal, in order to maintain mitochondrial integrity and function. As of today, there is no effective and clear therapeutic approach able to artificially manipulate mitochondrial dynamics, motility, or mitophagy, in order to ameliorate the overall condition and prolong the survival of patients affected by AD, PD, HD, and ALS. This said, innovative pharmacological tools or breakthrough systems, such as optogenetics, might help finding a feasible way to finely modulate mitochondria and mitophagy without impacting the global cell survival capacity.
